Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price range is set between RMB 37.99 and RMB 38.46 per share [1] Financial Implications - The total expenditure for the buyback reflects the company's strategy to enhance shareholder value [1]

Group 1 - The company, Lijun Pharmaceutical (01513), announced a share buyback plan to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price is set between RMB 37.99 and RMB 38.46 per share [1]

Core Viewpoint - Lijun Pharmaceutical (01513.HK) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 130,800 A-shares at a total cost of RMB 4.9979 million [1] - The buyback price per share ranges from RMB 37.99 to RMB 38.46 [1] Financial Implications - The total expenditure for the buyback represents a strategic investment in the company's own shares, potentially enhancing shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 2. 股份分類 | | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | | 說明 | | 人民幣股份 （於深圳證券交易所主板上市，股份代號：000513) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | | 2025年9月25日 | | 604,293,313 | | | 0 | | 604,2 ...

Group 1 - Company announced a share repurchase plan to buy back 129,300 A shares at a cost of RMB 5 million [1] - The repurchase price per share is set between RMB 38.49 and RMB 38.76 [1] - The repurchase is scheduled to take place on September 25, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫 ...

Group 1: Market Overview - The Shanghai Composite Index closed at 3853.64 points, with a gain of 0.83% on September 24, 2025 [2] - The Shenzhen Component Index rose by 1.80%, closing at 13356.14 points, while the ChiNext Index increased by 1.84% to 3921.15 points [2] - The total trading volume across major indices was approximately 10157.07 billion CNY for Shanghai and 13110.76 billion CNY for Shenzhen [2] Group 2: Media and Internet Industry - The media sector saw a weekly increase of 0.38%, outperforming the Shanghai and Shenzhen 300 Index, but underperforming the ChiNext Index [6] - Notable performers included Jishi Media and Guomai Culture, while companies like Happiness Blue Ocean and ST Huayang faced declines [6] - The film "731" achieved a box office of nearly 1 billion CNY within its first three days of release [7] Group 3: Investment Recommendations - The report suggests a positive outlook for the gaming sector and a potential bottom reversal in the film industry, emphasizing opportunities in AI applications [9] - Specific stock recommendations include Kaiying Network, G-bits, and Xindong Company in the gaming sector, and media companies like Focus Media and Bilibili [9] - The report highlights the importance of product cycles and performance in the gaming sector, alongside advertising growth driven by economic recovery [9] Group 4: LIZHU Group Financial Performance - LIZHU Group reported a revenue of 6.272 billion CNY for the first half of 2025, a slight decrease of 0.2%, while net profit increased by 9.4% to 1.281 billion CNY [10] - The chemical preparation segment generated 3.270 billion CNY in sales, with a gross margin of 81.17% [10] - The company is actively developing innovative products in various therapeutic areas, including digestive, reproductive, and neurological fields [12] Group 5: Clinical Trials and Product Development - LZM012, an IL-17A/F monoclonal antibody developed by LIZHU Group, showed superior efficacy in clinical trials for psoriasis compared to Secukinumab [11] - The company is advancing its pipeline with several products expected to reach the market, enhancing its competitive position [12] - Revenue projections for LIZHU Group are estimated at 12.337 billion CNY for 2025, with net profits expected to reach 2.199 billion CNY [12]

Group 1 - The core viewpoint of the article highlights the growth in China's chemical pharmaceutical raw material production, with a reported output of 329,000 tons in May 2025, reflecting a year-on-year increase of 3.8% [1] - Cumulative production of chemical pharmaceutical raw materials from January to May 2025 reached 1,585,000 tons, showing a cumulative growth of 5% [1] - The article references a report by Zhiyan Consulting, which provides insights into the market supply and demand trends in the Chinese chemical pharmaceutical industry from 2025 to 2031 [1] Group 2 - The listed companies in the article include Heng Rui Medicine, East China Medicine, Li Zhu Group, Baiyunshan, North China Pharmaceutical, Hai Zheng Pharmaceutical, Fosun Pharmaceutical, Ke Lun Pharmaceutical, En Hua Pharmaceutical, and Xian Ju Pharmaceutical [1] - Zhiyan Consulting is described as a leading industry consulting firm in China, specializing in in-depth industry research reports, business plans, feasibility studies, and customized services [1] - The article emphasizes Zhiyan Consulting's commitment to providing comprehensive industry solutions to empower investment decisions through professional insights and market acumen [1]

（来源：研报虎） 2025年上半年业绩逐步企稳，盈利能力持续提升。2025年上半年公司实现营收62.72亿元(-0.2%)，归母 净利润12.81亿元(+9.4%)，扣非归母净利润12.58亿元(+8.9%)。2025年二季度营收30.91亿元(+1.7%)，归 母净利润6.44亿元(+14.4%)，扣非归母净利润6.40(+13.2%)。 分板块看，2025年上半年化学制剂板块销售收入32.70亿元(+1.4%)，其中消化道药品销售额为13.51亿元 (+3.9%)，促性激素药品销售额为15.30亿元(-1.2%)，精神类药品销售额为3.17亿元(+6.9%)，抗感染及其 他产品销售额为0.72亿元(-7.4%)，板块整体的毛利率为81.17%(+0.02pp)；中药制剂2025年上半年销售收 入7.99亿元(+7.3%)，毛利率为74.0%(-1.57pp)；原料药及中间体2025年上半年销售收入16.62亿元 (-5.7%)，毛利率为36.37%(-0.76pp)；诊断试剂及设备产品2025年上半年销售收入3.74亿元(-5.1%)，生物 制品板块2025年上半年销售收入0.95亿元(+8.3%)。 I ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年9月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...